Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
J Endocrinol Invest ; 19(7): 455-62, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8884540

RESUMEN

Volume receptors are situated in many organs and are capable of modulating ADH secretion. We have evaluated the variation of plasma ADH concentration after an experimentally induced increase of cerebrospinal fluid (CSF) pressure (PCSF). The experiment was performed in controlled environmental conditions to avoid pain or stress-related ADH release. In 15 rats (10 experimental, 5 control) a cannula was positioned in the left cerebral ventricle: in the experimental group artificial CSF was infused at a rate of 0.6 (microliter/min for 6h: this manoeuvre, in a separate set of animals obtained an increase from 13.03 +/- 0.8 to 25.4 +/- 2.5 cmH2O of PCSF. The same conditions were reproduced in the control group without infusion into lateral ventricle. At the end of the experiment, plasma ADH had fallen significantly in the experimental group from 18.9 +/- 4.8 to 11.9 +/- 2.3 pg/ml (p < 0.05), while it was not changed in the control group (from 25.5 +/- 13.7 to 23.7 +/- 16.2 pg/ml). Heart rate, arterial pressure, plasma Na+ and osmolality, did not change significantly. Plasma K+ fell significantly in both groups: from 5.5 +/- 0.6 to 4.3 +/- 0.3 (p < 0.05) and from 5.4 +/- 0.7 to 4.3 +/- 0.15 mEq/l (p < 0.05) in the experimental and control group respectively. Plasma creatinine was normal, checked only at the end of the experiment. Our results demonstrate that a relationship exists between PCSF variations and plasma ADH concentration. We believe this relationship is due to the pressure receptors in the cerebral ventricles or in structures connected to it, such as the inner ear, and we hypothesize the existence of a control system of body fluids, more diffused than though to be, up till now.


Asunto(s)
Hemostáticos/sangre , Presión Intracraneal/fisiología , Seudotumor Cerebral/fisiopatología , Fármacos Renales/sangre , Vasopresinas/sangre , Animales , Presión Sanguínea/fisiología , Frecuencia Cardíaca/fisiología , Masculino , Seudotumor Cerebral/inducido químicamente , Ratas , Ratas Wistar , Factores de Tiempo
3.
Eur J Med ; 1(3): 153-7, 1992 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1341435

RESUMEN

OBJECTIVE: Data on parathyroid function in patients with homozygous beta-thalassaemia are discordant. Moreover, there is no report on the effects of sexual steroid treatment on bone metabolism in these patients. METHODS: Serum parathyroid hormone (PTH), calcitonin (CT) and osteocalcin (GLA protein) levels were measured in 121 patients. Thirty-three prepubertal subjects were treated for six months with sexual steroids. RESULTS AND CONCLUSIONS: Primary hypoparathyroidism was present in 3.3% of the patients. Osteocalcin levels were found to be lower in thalassaemic subjects than in controls, whereas CT values were similar. No effects of sexual steroid administration on plasmatic levels of osteocalcin were observed.


Asunto(s)
Huesos/metabolismo , Estrógenos Conjugados (USP)/uso terapéutico , Hipoparatiroidismo/fisiopatología , Glándulas Paratiroides/fisiopatología , Testosterona/uso terapéutico , Talasemia beta/tratamiento farmacológico , Talasemia beta/fisiopatología , Adolescente , Adulto , Enfermedades Óseas Metabólicas/etiología , Enfermedades Óseas Metabólicas/prevención & control , Huesos/efectos de los fármacos , Calcitonina/sangre , Niño , Femenino , Trastornos del Crecimiento/etiología , Trastornos del Crecimiento/prevención & control , Humanos , Hipoparatiroidismo/complicaciones , Masculino , Osteocalcina/sangre , Osteocalcina/efectos de los fármacos , Hormona Paratiroidea/sangre , Pubertad Tardía/etiología , Pubertad Tardía/prevención & control , Talasemia beta/complicaciones , Talasemia beta/metabolismo
4.
Acta Endocrinol (Copenh) ; 125(5): 494-501, 1991 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-1759539

RESUMEN

UNLABELLED: Forty-one patients with prolactinoma (25 micro-, 16 macroprolactinomas) were treated with a long-acting injectable preparation of bromocriptine (Parlodel LAR, Sandoz), 25-100 mg (mostly 50 mg) in every 4-8 weeks for as long as 43 months (median 19 months). The first injection caused a prompt fall of plasma PRL which reached its nadir value after 3 days. Thereafter, hormone levels remained well below initial values for 4 weeks or longer, though with the tendency, more pronounced in microprolactinoma patients, to rise again toward baseline. The prevalence of PRL normalization was greater in the macro- than in the microprolactinoma group. By repeated injections plasma PRL could be kept close to or within the normal limits in most of the patients. However, the extent of PRL inhibition was significantly greater in macro- than in microprolactinoma patients (p less than 0.01). Clinical improvement occurred in the majority of the patients, shrinkage of the tumour in 50% of them. Adverse reactions were generally mild or of moderate severity and subsided spontaneously in 24 h. They were less frequent (NS) and less severe (p less than 0.05) in macro- than in microprolactinoma patients. IN CONCLUSION: a. injectable bromocriptine (Parlodel LAR) is a highly effective preparation particularly suitable for the long-term treatment of tumourous hyperprolactinemia; b. patients with macroprolactinoma exhibit, compared with microprolactinoma patients, better responsiveness and better tolerability to injectable bromocriptine.


Asunto(s)
Bromocriptina/uso terapéutico , Neoplasias Hipofisarias/tratamiento farmacológico , Prolactina/metabolismo , Prolactinoma/tratamiento farmacológico , Adolescente , Adulto , Anciano , Bromocriptina/administración & dosificación , Bromocriptina/efectos adversos , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Inyecciones , Masculino , Persona de Mediana Edad , Neoplasias Hipofisarias/metabolismo , Prolactina/sangre , Prolactinoma/metabolismo
5.
Horm Res ; 35(3-4): 137-41, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1806467

RESUMEN

The efficacy and tolerability of a slow-release preparation of bromocriptine (Parlodel SRO) were compared to those of conventional bromocriptine (Parlodel R) in a double blind, double dummy study of 12 hyperprolactinemic women (plasma PRL 81.3 +/- 4.73, ng/ml mean +/- SEM). For 2 weeks, the patients received 2.5 mg b.i.d. Parlodel R or 5 mg once daily Parlodel SRO; for the following 2 weeks, the dose of the drugs was doubled. The patients were then treated, in an open study, with 2.5-10 mg daily Parlodel SRO for 6 months. Both preparations caused a prompt and sharp PRL fall. Hormone levels remained inhibited over the whole month of observation with both preparations. Daily PRL profiles were very close with either drug although morning PRl levels were slightly higher during Parlodel SRO than during Parlodel R administration. Doubling the doses of the two drugs did not result in further significant lowering of PRL values. During the 6-month study with Parlodel SRO, plasma PRL further decreased and normalized in 11 of 12 patients. Clinical improvement occurred in the majority of cases. Tolerability of Parlodel SRO appeared to be better, though without statistically significant differences, than that of Parlodel R. Side effects were less important with the former compound in their number, severity and duration. In conclusion, thanks to its favourable pharmacological profile, Parlodel SRO appears to be a valuable alternative to regular bromocriptine in the management of hyperprolactinemia.


Asunto(s)
Bromocriptina/uso terapéutico , Hiperprolactinemia/tratamiento farmacológico , Administración Oral , Adulto , Bromocriptina/administración & dosificación , Preparaciones de Acción Retardada , Método Doble Ciego , Femenino , Humanos , Hiperprolactinemia/sangre , Hiperprolactinemia/fisiopatología , Trastornos de la Menstruación/etiología , Prolactina/sangre
7.
Int J Sports Med ; 8(6): 407-14, 1987 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-3429087

RESUMEN

Two groups of subjects were examined: trained athletes (group A) and a sedentary control group (group B). The subjects performed submaximal bicycle exercise in the semisupine position to evaluate the differences between the two groups with regard to cardiovascular response during exercise and recovery and to point out all the changes due to training. During the first part of exercise, cardiac output increased contemporary with heart rate and myocardial contractility as shown by the trend of the ejection fraction, higher in group A, under the same level of total vascular peripheral resistances. Later there was an increase of cardiac output for a further increase of heart rate and cardiac inotropism due to the homeometric mechanism. During recovery the heart rate and peripheral vascular resistance reduction led to an increase of venous return which set up the Frank-Starling mechanism via an increase of left ventricular dimensions. These adjustments were more efficient in group A. During exercise and recovery the heart rate-pressure product was constantly lower in group A with a significant difference to group B. Therefore, trained athletes' myocardium is more efficient than that of the sedentary group because it performs an external work load with a lower oxygen consumption.


Asunto(s)
Hemodinámica , Educación y Entrenamiento Físico , Esfuerzo Físico , Postura , Adulto , Animales , Ecocardiografía , Estudios de Evaluación como Asunto , Prueba de Esfuerzo , Fútbol Americano , Ventrículos Cardíacos/anatomía & histología , Humanos , Contracción Isotónica , Ratones , Función Ventricular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA